{"id":56086,"date":"2026-02-02T22:40:06","date_gmt":"2026-02-02T14:40:06","guid":{"rendered":"https:\/\/flcube.com\/?p=56086"},"modified":"2026-02-02T22:40:07","modified_gmt":"2026-02-02T14:40:07","slug":"illumina-completes-350m-somalogic-acquisition-to-expand-proteomics-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56086","title":{"rendered":"Illumina Completes $350M SomaLogic Acquisition to Expand Proteomics Portfolio"},"content":{"rendered":"\n

Illumina<\/strong> (NASDAQ:\u202fILMN<\/a>) announced the completion of its acquisition of SomaLogic<\/strong>, a leader in data\u2011driven proteomics technology, from Standard BioTools<\/strong>. The deal, first announced in June\u202f2025<\/strong>, integrates highly complementary proteomics capabilities, expanding Illumina\u2019s multi\u2011omics product portfolio and accelerating drug development insights.<\/p>\n\n\n\n

Transaction Structure & Deal Terms<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Acquirer<\/strong><\/td>Illumina, Inc. (NASDAQ:\u202fILMN)<\/td><\/tr>
Target<\/strong><\/td>SomaLogic (from Standard BioTools)<\/td><\/tr>
Base Purchase Price<\/strong><\/td>USD\u202f350\u202fmillion in cash<\/td><\/tr>
Milestone Payments<\/strong><\/td>Up to USD\u202f75\u202fmillion in near\u2011term performance milestones<\/td><\/tr>
Additional Consideration<\/strong><\/td>Performance\u2011based royalties<\/td><\/tr>
Payment Terms<\/strong><\/td>Cash payable upon completion, subject to customary adjustments<\/td><\/tr>
Strategic Rationale<\/strong><\/td>Expand multi\u2011omics portfolio, integrate proteomics capabilities<\/td><\/tr>
Technology Focus<\/strong><\/td>Data\u2011driven proteomics technology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Value & Market Impact<\/h2>\n\n\n\n